Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S.M. Handunnetti
An Undetectable Pb MRD Status Should Be the Therapeutic Goal With Venetoclax Therapy in Relapsed/ Refractory CLL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax: Another Oral Therapy Option for Patients With CLL
Pharmacy Today
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Relapsed/Refractory ETP-all Successfully Treated With Novel Combination Therapy Venetoclax With Nelarabine Prior to Allogeneic Stem Cell Transplant
Pathology
Forensic Medicine
Pathology
Clinical Experience With the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies
American Journal of Hematology
Hematology
Rescue Therapy for Refractory ARDS Should Be Offered Early: No
Intensive Care Medicine
Critical Care
Intensive Care Medicine
Rescue Therapy for Refractory ARDS Should Be Offered Early: Yes
Intensive Care Medicine
Critical Care
Intensive Care Medicine
Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Phase Ib/Ii Study of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
